Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Inclusion Criteria:

* Histologically or cytologically confirmed malignant brain tumor
* Disease must be considered refractory to first line or relapsing after conventional therapy and for which no effective conventional treatment exists.·
* Newly diagnosed, histologically proven brain stem glioma, except pilocytic astrocytomas.
* Age: 1 to ≤ 21 years of age at study entry
* Life expectancy: at least 8 weeks
* ECOG Performance status ≤ 1 or Lansky-Play Scale\>= 70%, and including children with motor paresis due to disease
* Measurable or evaluable disease
* No other serious concomitant illness
* No organ toxicity \> grade 2 NCI-CTC AE v3.0, except alopecia and neurological symptoms due to disease

Exclusion Criteria:

* Patients with spontaneous intratumoral hemorrhage will not be included in the study, in exception of small post-biopsy hemorrhage due to biopsy procedure
* Pregnant and breast feeding woman
* Uncontrolled intercurrent illness or active infection
* Chemotherapy within 4 weeks prior to study medication (within 6 weeks, if the regimen contained a nitrosourea)
* Radiation therapy within 6 weeks prior to study medication
* Any clinical or non-clinical evidence of pulmonary dysfunction or pre-existing lung disease
* Severe cardiac pathology; history of myocardial infarction within the year prior to inclusion
* Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
* Treatment with Coumarin (warfarin)